Abstract: A first processor is connected to a first filter on a tractor and receives at least one control signal from at least one vehicle control. The first processor communicates the control signal to the trailer component. A second processor is connected to a second filter on a trailer. The second filter is interconnected between the second processor and the trailer component. A sensor on the trailer is connected to the second processor and generates a sensor signal. A wiring harness communicates with the first filter and the vehicle control on the tractor and with the second filter and the trailer component. The wiring harness has common wires that carry the control signal from the first filter to the trailer component via the second filter. The common wires carry the sensor signal transformed by the second processor from the second filter to the first processor via the first filter.

Abstract: A trailer communication system has a wiring harness configured to carry a plurality of control signals and a connector configured to communicate with a tractor. A sensor is configured to generate a sensor signal. A processor is interconnected between the sensor and the wiring harness, the processor configured to transform the sensor signal for transmission over the wiring harness with at least one of the plurality of control signals using common wires within the wiring harness. The processor is further configured to receive the plurality of control signals and to generate a command to a corresponding one of a plurality of trailer components based upon the plurality of control signals.

Abstract: The present invention relates to a conjugate having the formula (1): wherein a receptor binding molecule (RBM) is connected with a drug moiety (D), the conjugate comprising a phosphorus(V) moiety. The present invention also relates to intermediates for producing the same, methods of preparing the same, pharmaceutical compositions comprising the same, as well as uses thereof.

Abstract: The present invention relates to novel anti-TPBG antibody comprising Fc silencing mutations such as leucine (L) to alanine (A) substitution at the position 234 and 235 (LALA mutations), antibody-drug-conjugates (ADCs) based thereon as well as to therapeutic methods and uses thereof, particularly in relation to cancer treatment.

Abstract: The present invention relates to novel anti-NaPi2b antibodies, novel antibody-drug-conjugates (ADCs) based thereon as well as to therapeutic methods and uses thereof, particularly in relation to cancer treatment.

Abstract: The present invention relates to novel anti-NaPi2b antibodies, antibody-drug-conjugates (ADCs) based thereon as well as to therapeutic methods and uses thereof, particularly in relation to cancer treatment.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: The present invention relates to a conjugate having the formula (I): wherein a receptor binding molecule (RBM) is connected with a drug moiety (D). The present invention also relates to intermediates for producing the same, methods of preparing the same, pharmaceutical compositions comprising the same, as well as uses thereof.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: The present invention relates to a conjugate having the formula (I): wherein a receptor binding molecule (RBM) is connected with a camptothecin moiety (C). The present invention also relates to intermediates for producing the same, methods of preparing the same, pharmaceutical compositions comprising the same, as well as uses thereof.

Abstract: The present invention provides means and methods for functionalizing a polypeptide of interest at its C-terminus with an amino acid derivative.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: The present invention relates to an antibody-drug conjugate (ADC) comprising: (a) Brentuximab, wherein Brentuximab comprises at the C-terminus of the light chains, the heavy chains or all of the heavy and light chains of the Brentuximab a recognition sequence for tubulin tyrosine ligase and a non-natural amino acid; and (b) at least one drug moiety; wherein a drug moiety is coupled to each of the non-natural amino acids via a linker. The present invention further relates to methods of producing same, pharmaceutical compositions comprising same as well as uses thereof.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process tor the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III), with an azide of formula (IV), to prepare a compound of formula (V), reacting a compound of formula (V) with a thiol-containing molecule of formula (VI), resulting in a compound of formula (VII).

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.

Abstract: Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosohonothiolates and -phosphonates comprises the step of: reacting a compound of formula (I) with a thiol-containing molecule of formula (II) wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; resulting in a compound of formula (III).

Abstract: The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.